BPCE
CRSP icon

Bank Pictet & Cie (Europe)’s CRISPR Therapeutics CRSP Stock Holding History

Bank Pictet & Cie (Europe)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,519
Closed -$284K – 163
2022
Q1 		$284K Buy
4,519
+443
+11% +$27.8K 0.01% 146
2021
Q4 		$309K Buy
4,076
+532
+15% +$46.5K 0.01% 146
2021
Q3 		$397K Sell
3,544
-333
-9% -$41.8K 0.01% 139
2021
Q2 		$628K Buy
+3,877
New +$472K 0.02% 125

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank Pictet & Cie (Europe)'s CRSP Position: Q2 2022 in Review

Bank Pictet & Cie (Europe) sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 4,519 shares — an estimated $284K sold.

Bank Pictet & Cie (Europe) first reported a position in CRSP in Q2 2021 and held it in 4 quarters. The position peaked at $628K in Q2 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • Bank Pictet & Cie (Europe) reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bank Pictet & Cie (Europe) sold 4,519 CRISPR Therapeutics shares in Q2 2022, an estimated $284K.
  • Bank Pictet & Cie (Europe) first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 4 quarters.
  • Bank Pictet & Cie (Europe)'s CRISPR Therapeutics position peaked at $628K in Q2 2021.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Bank Pictet & Cie (Europe)'s 13F filing for Q2 2022, filed 5 Aug 2022.